Afatinib with concurrent radiotherapy in a patient with metastatic non-small cell lung cancer.
BACKGROUND
The combination of radiotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) has not been widely investigated. For afatinib, a new second generation irreversible pan-EGFR TKI, no clinical trials in this setting have as yet been performed.


METHODS
We report a patient with a pretreated metastatic NSCLC receiving afatinib in combination with concomitant palliative radiotherapy to the mediastinum and primary lung tumor. The treatment was feasible and well tolerated. The patient achieved a partial response in the irradiated tumor region and the metastatic sites.


CONCLUSIONS
The combination of afatinib and radiotherapy is promising and should be investigated further. However, because of the limited experience and potential side effects known for other EGFR TKIs, a decision for treatment outside a clinical trial has to be made very carefully, balancing the risk and benefit on an individual patient basis.
Department of Oncology and Hematology, Krankenhaus Nordwest, UCT University Cancer Center, Frankfurt/M., Germany.
Akin
A
Atmaca
Salah-Eddin
SE
Al-Batran
Michael
M
Allgäuer
Elke
E
Jäger
D000077716:Afatinib; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000556:secondary* / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D011799:Quinazolines / Q000627:therapeutic use*; D020266:Radiotherapy, Conformal / Q000379:methods; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D011799:Quinazolines; D000077716:Afatinib